摘要
Introduction & Background
After cerebral ischemia, lactate accumulation in astrocytes may limit mitochondrial transfer to injured neurons and thereby exacerbate neuronal energy deficits. We therefore developed AS1–Ru–MnCO₃/LOx, an astrocyte-targeted nanozyme designed to promote lactate oxidation and reduce oxidative stress. This study aimed to determine whether the nanozyme could enhance astrocyte-to-neuron mitochondrial transfer and improve neuronal energy metabolism after cerebral ischemia.
Methods
Ru-doped manganese carbonate (Ru–MnCO₃) was loaded with lactate oxidase (LOx) and functionalized with the astrocyte-targeting peptide AS1. The nanozyme was characterized by transmission electron microscopy (TEM), dynamic light scattering (DLS), and X-ray photoelectron spectroscopy (XPS). Catalytic activity was measured using assay kits.
After oxygen–glucose deprivation/reoxygenation (OGD/R), astrocytes were assessed for mitochondrial membrane potential (JC-1), intracellular ROS (DCFH-DA), mitochondrial superoxide (MitoSOX), and apoptosis. In OGD/R-treated astrocyte–neuron co-cultures, we tracked astrocyte-derived mitochondria through tunneling nanotubes (TNTs) and measured MFN2, OPA1, and DRP1 expression, oxygen consumption rate (OCR), and extracellular acidification rate (ECAR).
In mice that underwent transient middle cerebral artery occlusion (tMCAO), ischemic brain lactate levels, mitochondrial ultrastructure (TEM), and neurological function were assessed. Brain injury was evaluated by Nissl and TTC staining and NeuN, MAP2, and PSD95 immunostaining.
Results
AS1–Ru–MnCO₃/LOx was synthesized and characterized (TEM, DLS, XPS) and exhibited CAT- and SOD-like activities.
AS1–Ru–MnCO₃/LOx attenuated mitochondrial depolarization and apoptosis and lowered intracellular ROS and mitochondrial superoxide levels in OGD/R-treated astrocytes. In OGD/R-treated co-cultures, astrocyte-derived mitochondria were visualized within TNTs. Treatment increased astrocyte-to-neuron mitochondrial transfer and improved co-culture bioenergetics. It also increased MFN2 and OPA1 expression and decreased DRP1 expression, consistent with a shift toward mitochondrial fusion.
In tMCAO mice, AS1–Ru–MnCO₃/LOx lowered ischemic brain lactate levels, reduced infarct volume, and improved neurological function. TEM revealed less mitochondrial swelling and ultrastructural damage, and histology showed better preservation of neuronal structure.
Conclusions
AS1–Ru–MnCO₃/LOx improved neuronal energy metabolism and reduced ischemic brain injury in tMCAO mice, supporting its therapeutic potential for ischemic stroke.
